GlassScriptPhysician profile
Christine Hwang
NPI 1265213532
$8,380.40
in general payments reported to CMS, 2019-2025
58 companies · $4,746 in 2025
The $4,746 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,635 · 2025: $4,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,691 · Education: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,691.24 |
| Education | $689.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $863.15 | 2024-2025 | Imfinzi, Enhertu, Datroway |
| Pfizer INC. | $702.03 | 2024-2025 | |
| Incyte Corporation | $659.17 | 2024-2025 | Monjuvi, Jakafi, Monjuvi |
| Janssen Biotech, INC. | $567.61 | 2024-2025 | Erleada, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $480.69 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $408.82 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $340.97 | 2024-2025 | Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $317.78 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $313.96 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $297.75 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.37 | 2024-2025 | Fruzaqla, Ninlaro, Hyqvia |
| Lilly USA, LLC | $220.11 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Beone Medicines USA, INC. | $172.14 | 2025 | Brukinsa, Tevimbra |
| Agios Pharmaceuticals, INC. | $168.27 | 2024 | Pyrukynd |
| Sobi, INC | $144.56 | 2024-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $142.91 | 2024-2025 | Opdivo, Opdualag |
| Sumitomo Pharma America, INC. | $130.65 | 2024-2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $127.71 | 2024-2025 | |
| Amgen INC. | $121.85 | 2025 | Blincyto |
| Celgene Corporation | $114.60 | 2024-2025 | Reblozyl, Opdualag, Pomalyst |
| Pharmacosmos Therapeutics INC. | $103.47 | 2024-2025 | Cosela, Monoferric |
| Gilead Sciences, INC. | $99.67 | 2024-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.71 | 2024-2025 | Gilotrif |
| Array Biopharma INC | $83.49 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $83.41 | 2024-2025 | Ultomiris |
| Seagen INC. | $77.99 | 2025 | |
| Jazz Pharmaceuticals INC. | $77.81 | 2024-2025 | |
| Taiho Oncology, INC. | $67.37 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $64.87 | 2024-2025 | |
| Geron Corporation | $64.75 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $60.25 | 2024 | |
| Abbvie INC. | $58.26 | 2024-2025 | |
| Fennec Pharmaceuticals, INC. | $57.49 | 2024 | Pedmark |
| Immunocore Limited | $57.12 | 2025 | Kimmtrak |
| Exelixis INC. | $56.58 | 2024 | Cabometyx |
| Stemline Therapeutics INC. | $54.00 | 2024-2025 | Orserdu |
| Genzyme Corporation | $50.23 | 2024-2025 | |
| Genmab U.S., INC. | $49.50 | 2024-2025 | Epkinly |
| Emd Serono, INC. | $49.24 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $48.25 | 2025 | Myrisk, Precisetumor |
| Dendreon Pharmaceuticals LLC | $46.67 | 2025 | Provenge |
| Acrotech Biopharma INC. | $45.68 | 2024-2025 | Beleodaq |
| Janssen Scientific Affairs, LLC | $41.67 | 2025 | Darzalex, Carvykti, Tecvayli |
| Genentech USA, INC. | $34.79 | 2025 | Venclexta |
| Tempus Ai, INC | $34.74 | 2024-2025 | Xt Cdx |
| Legend Biotech USA INC. | $31.75 | 2025 | Carvykti |
| Napo Pharmaceuticals INC | $27.46 | 2024 | Gelclair Concentrated Oral Gel |
| Regeneron Healthcare Solutions, INC. | $24.04 | 2025 | Libtayo |
| Amneal Pharmaceuticals LLC | $20.92 | 2025 | Pemrydi Rtu |
| Deciphera Pharmaceuticals INC. | $19.94 | 2024 | Tgct, Qinlock |
| Progenics Pharmaceuticals, INC. | $18.97 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.90 | 2025 | Onivyde |
| Morphosys, US INC. | $17.60 | 2024 | Monjuvi |
| Shield Therapeutics INC | $16.28 | 2025 | |
| Blueprint Medicines Corporation | $15.01 | 2025 | Ayvakit |
| Puma Biotechnology, INC. | $14.35 | 2025 | |
| Menarini Silicon Biosystems, INC. | $14.33 | 2025 | |
| Kite Pharma, INC. | $13.74 | 2025 | Yescarta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.